AKAP9

Across TCGA pan-cancer cohorts, AKAP9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKAP9 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AKAP9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AKAP9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

HNSC, UCEC, and COAD are the cancer types where AKAP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.496	0.776	.001	32	view →
UCEC	DFS	Median	II,III,IV	0.926	0.487	.004	20	view →
COAD	DFS	Median	II,III,IV	1.000	0.880	.019	18	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	13	view →
LUAD	DFS	Tertile	II,III,IV	0.968	0.685	.008	7	view →
LSCC	DFS	Quartile	All	0.703	0.886	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKAP9–HNSC (OS)

Open the HNSC breakdown →